Myfortic
(mycophenolate sodium)Phase 3Small molecule
NovartisMycophenolate sodium is used to prevent the body's immune system from rejecting transplanted organs, particularly kidneys. It's also used to treat certain autoimmune conditions like lupus.[1] Myfortic is currently being investigated across 15 indications[3], with its most advanced program in Phase 3.[1]
Myfortic is one of 370 small molecule programs targeting Liver Transplant. It is currently in Phase 3.
15
Indications
71
Total Trials
4
Active Trials
369
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 15 indications
Competition
Competitive Landscape
560 competitors in Multiple Sclerosis
#DrugCompanyPhaseTrials
1Myfortic
NovartisPhase 3
Betaseron
BayerPreclinical
Tysabri
BiogenPreclinical
Avonex
EMD SeronoPreclinical
Flomax
SanofiPreclinical
Pred Forte
NovartisPreclinical
Circadin
NNeurim Pharmaceuticals Ltd.
Preclinical
Wellcovorin
GGlaxo Dba Glaxosmithkline
Preclinical
Pletal
OtsukaPreclinical
Proair HFA
GGlaxo Dba Glaxosmithkline
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Kidney Transplant20 trials
Show 17 more trials
Renal Transplant Recipients11 trials
Show 8 more trials
Renal Transplant11 trials
Show 8 more trials
Pharmacokinetics of Everolimus and Enteric-Coated Mycophenolatesodium Before and After Withdrawal of Cyclosporine in Renal Transplant Patients
Completed·—·Phase 4·NCT00443937·15 enrolled
Efficacy and Safety3 trials
ESS3 trials
19 more indications
Lupus Nephritis2 trials
The Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) (Myfortic) in The Treatment of Relapse or Resistant Proliferative Lupus Nephritis
Terminated·—·Phase 3·NCT01015456·59 enrolled
Gastrointestinal2 trials
Safety and Efficacy2 trials
Liver Transplant2 trials
Hematological Malignancies1 trial
Primary Sjogren's Syndrome1 trial
Transplant Recipient1 trial
Enteric-coated Mycophenolate Sodium (Myfortic®) in Heart Transplant Recipients
Completed·—·Phase 4·NCT00574197·11 enrolled
Maintenance Therapy1 trial
Transplantation1 trial
Steroid1 trial
Heart Transplant1 trial
Lupus1 trial
Autoimmune Disease1 trial
Renal Allograft Recipients1 trial
Kidney Transplant Rejection1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for mycophenolate sodium. EMBL-EBI & Wellcome Sanger Institute.
- [4]